No abstract

Ultralight multiwalled carbon nanotube (MWCNT) aerogel is fabricated from a wet gel of well-dispersed pristine MWCNTs. On the basis of a theoretical prediction that increasing interaction potential between CNTs lowers their critical concentration to form an infinite percolation network, poly(3-(trimethoxysilyl) propyl methacrylate) (PTMSPMA) is used to disperse and functionalize MWCNTs where the subsequent hydrolysis and condensation of PTMSPMA introduces strong and permanent chemical bonding between MWCNTs. The interaction is both experimentally and theoretically proven to facilitate the formation of a MWCNT percolation network, which leads to the gelation of MWCNT dispersion at ultralow MWCNT concentration. After removing the liquid component from the MWCNT wet gel, the lightest ever free-standing MWCNT aerogel monolith with a density of 4 mg/cm(3) is obtained. The MWCNT aerogel has an ordered macroporous honeycomb structure with straight and parallel voids in 50-150 μm separated by less than 100 nm thick walls. The entangled MWCNTs generate mesoporous structures on the honeycomb walls, creating aerogels with a surface area of 580 m(2)/g which is much higher than that of pristine MWCNTs (241 m(2)/g). Despite the ultralow density, the MWCNT aerogels have an excellent compression recoverable property as demonstrated by the compression test. The aerogels have an electrical conductivity of 3.2 × 10(-2) S·cm(-1) that can be further increased to 0.67 S·cm(-1) by a high-current pulse method without degrading their structures. The excellent compression recoverable property, hierarchically porous structure with large surface area, and high conductivity grant the MWCNT aerogels exceptional pressure and chemical vapor sensing capabilities.

A bioengineered spinal cord is fabricated via extrusion-based multimaterial 3D bioprinting, in which clusters of induced pluripotent stem cell (iPSC)derived spinal neuronal progenitor cells (sNPCs) and oligodendrocyte progenitor cells (OPCs) are placed in precise positions within 3D printed biocompatible scaffolds during assembly. The location of a cluster of cells, of a single type or multiple types, is controlled using a point-dispensing printing method with a 200 µm center-to-center spacing within 150 µm wide channels. The bioprinted sNPCs differentiate and extend axons throughout microscale scaffold channels, and the activity of these neuronal networks is confirmed by physiological spontaneous calcium flux studies. Successful bioprinting of OPCs in combination with sNPCs demonstrates a multicellular neural tissue engineering approach, where the ability to direct the patterning and combination of transplanted neuronal and glial cells can be beneficial in rebuilding functional axonal connections across areas of central nervous system (CNS) tissue damage. This platform can be used to prepare novel biomimetic, hydrogel-based scaffolds modeling complex CNS tissue architecture in vitro and harnessed to develop new clinical approaches to treat neurological diseases, including spinal cord injury.

The development of 3D in vitro models capable of recapitulating native tumor microenvironments could improve the translatability of potential anticancer drugs and treatments. Here, 3D bioprinting techniques are used to build tumor constructs via precise placement of living cells, functional biomaterials, and programmable release capsules. This enables the spatiotemporal control of signaling molecular gradients, thereby dynamically modulating cellular behaviors at a local level. Vascularized tumor models are created to mimic key steps of cancer dissemination (invasion, intravasation, and angiogenesis), based on guided migration of tumor cells and endothelial cells in the context of stromal cells and growth factors. The utility of the metastatic models for drug screening is demonstrated by evaluating the anticancer efficacy of immunotoxins. These 3D vascularized tumor tissues provide a proof‐of‐concept platform to i) fundamentally explore the molecular mechanisms of tumor progression and metastasis, and ii) preclinically identify therapeutic agents and screen anticancer drugs.